{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anastrozole",
    "query": {
      "intervention": "anastrozole"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 223,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anastrozole&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T00:26:07.361Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06154590",
      "title": "Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Breast Cancer",
        "Tumor",
        "Muscle Neoplasms",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Method(s)1 Attribution",
          "type": "DRUG"
        },
        {
          "name": "Method(s)2 Attribution,",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DR. DIANE CHISESI NFS. MD. PHD.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "44 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "44 Years to 59 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-07",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2023-12-04",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 1,
      "location_summary": "Colorado Springs, Colorado",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06154590"
    },
    {
      "nct_id": "NCT01776008",
      "title": "Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Recurrent Breast Carcinoma",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Neoadjuvant Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2013-01",
      "completion_date": "2015-05-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-08",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01776008"
    },
    {
      "nct_id": "NCT03304080",
      "title": "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Diseases"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2017-12-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 5,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03304080"
    },
    {
      "nct_id": "NCT06086340",
      "title": "Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Aromatase Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 779,
      "start_date": "2023-09-29",
      "completion_date": "2024-01-24",
      "has_results": true,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06086340"
    },
    {
      "nct_id": "NCT02291913",
      "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Toremifine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2014-12-18",
      "completion_date": "2019-01-31",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 8,
      "location_summary": "Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Terre Haute",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02291913"
    },
    {
      "nct_id": "NCT03822468",
      "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 376,
      "start_date": "2019-06-11",
      "completion_date": "2024-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 14,
      "location_summary": "Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822468"
    },
    {
      "nct_id": "NCT00133354",
      "title": "Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hypopituitarism"
      ],
      "interventions": [
        {
          "name": "Arimidex (Anastrozole)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Growth Hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "11 Years to 18 Years · Male only"
      },
      "enrollment_count": 53,
      "start_date": "2001-11",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2011-10-12",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00133354"
    },
    {
      "nct_id": "NCT00433173",
      "title": "Insulin Sensitivity in Men With the Metabolic Syndrome",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "intravenous glucose tolerance test",
          "type": "PROCEDURE"
        },
        {
          "name": "testosterone",
          "type": "DRUG"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate implant",
          "type": "DRUG"
        },
        {
          "name": "aerobic capacity (VO2 Max)",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "muscle biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "measurement of resting metabolic rate (energy expenditure)",
          "type": "PROCEDURE"
        },
        {
          "name": "Dual energy x-ray absorptiometry",
          "type": "PROCEDURE"
        },
        {
          "name": "Fasting oral glucose tolerance test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "50 Years to 75 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2006-05",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433173"
    },
    {
      "nct_id": "NCT00022672",
      "title": "A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab (Herceptin®)",
          "type": "DRUG"
        },
        {
          "name": "anastrazole (Arimidex®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 208,
      "start_date": "2001-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-06-13",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022672"
    },
    {
      "nct_id": "NCT02137837",
      "title": "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2014-05",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-09-02T00:26:07.361Z",
      "location_count": 223,
      "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02137837"
    }
  ]
}